1. Introduction {#sec1}
===============

Overweight/obesity, type 2 diabetes mellitus (T2DM), and cardiovascular diseases (CVDs) are rapidly increasing in Asian Indians, and these are accompanied by multiple other cardiovascular risk factors including hypertension and dyslipidemia \[[@B1], [@B2]\]. Moreover, such dysmetabolic state occurs early and rapidly deteriorates from the second decade of life \[[@B3]\]. These conditions are majorly contributed by imbalanced diet (high carbohydrates, high saturated fats, low fiber, etc.), physically inactive lifestyle, and stress \[[@B4]\]. Specifically, some segments of the population (women and people belonging to middle and low socioeconomic strata) are increasingly becoming vulnerable to obesity and clustering of cardiovascular risk factors (metabolic syndrome) in India \[[@B5]\]. Many other sections of the population, such as corporate and industrial workforce, have not been adequately investigated.

The workforce in industrial and corporate sectors is increasing in India. Many of such individuals do desk-based jobs and commute in motorized vehicles for long distances leaving little time for physical activity. Moreover, for most of the days, their food intake during office hours is based on availability of often unhealthy food articles in office cafeteria. However, their health status with particular reference to cardiovascular risk factors remains sparsely researched. In a study done on two industrial units in South India (*n*, 2262, males), 67% was overweight/obese, 70% had abdominal obesity, 27% had hypertension, 30% had high cholesterol, and 16% had T2DM \[[@B6]\]. These data raise concern and increase need for more research in the context of cardiovascular risk factors in workforce in industrial and corporate sectors in India. In particular, food habits, physical activity, obesity measures, and metabolic status of people working in these sectors need to be ascertained \[[@B6]\].

Worksite intervention remains an effective way of reducing cardiometabolic risk factors. Improving health in the workforce should not only benefit the employee but also may increase productivity, thus benefiting the employer as well. Most of the intervention studies included changes in weight and body mass index (BMI) as outcome measures, while others have focused on physical activity and diet. Almost half of the all the studies were undertaken in the USA and the rest in Europe, Iceland, Canada, Australia, New Zealand, and Japan but very few have been conducted in India. In a systematic review, a total of 47 studies (*n* = at least 76,941) were included, comprising of 24 randomized controlled trials (RCTs), seven cluster randomized controlled trials, 12 nonrandomized, three cohort studies, and one-time series. The authors summarized that the worksite nutrition and physical activity programmes achieved modest improvements in employee weight status at 6 to 12 months of follow-up. Analysis of RCTs showed that the interventions resulted in a decrease in weight of 2.80 pounds (95% CI −4.63 to −0.96; nine studies) and a reduction in BMI of −0.47 kg/m^2^ (95% CI −0.75 to −0.19; six studies) compared to the controls. Importantly, these findings are applicable to both genders and across wide variety of worksites. While most studies have combined informational and behavioural strategies for diet and physical activity, lesser number is focused on different areas of work environment \[[@B7]\].

Because of paucity of data, specifically interventions in a randomized manner in Asian Indians working in a corporate setup, we conducted 6-month intervention trial on employees in the age group of 25--55 years at different worksites at New Delhi, India. The primary objective of our study was to observe the effect of multicomponent lifestyle interventions on weight loss, and the secondary objective was to observe the changes in body fat patterning and reduction of cardiometabolic risk factors in at-risk, overweight individuals.

2. Material and Methods {#sec2}
=======================

2.1. Sample Size Calculation {#sec2.1}
----------------------------

This was a prospective comparative study having an intervention group and a control group. The objective of the study was to test whether the intervention has resulted into desired improvements in the parameters as compared to the control groups. Of various indicators, the BMI was the main indicator for the study.

The following assumptions have been made in deciding the sample size: Mean change in the value of the parameters (BMI) for the intervention group (Δ~1~) = 0.50.Mean change in the value of the parameters (BMI) for the control group (Δ~2~) = 0.10.The standard deviation of the change in the parameters for the intervention group (*σ*~1~) = 1.0.The standard deviation of the change in the parameters for the control group (*σ*~2~) = 0.90.

Confidence level = 95% and power = 90%. The ratio of sample size (intervention versus control) = 1.5. For detecting the difference of 0.4 between groups as significant, the sample size works out as 160 for the intervention group and 107 for the control group. The study was planned so as to achieve this sample size; however, the realized sample size is 156 for the intervention group and 111 for the control group.

Sample size calculation was done by the following: $$\begin{matrix}
{n = \frac{\left( {{\sigma_{1}}^{2} + {\sigma_{1}}^{2}} \right)\left( {Z_{\alpha} + Z_{\beta}} \right)^{2}}{\left( {\Delta_{1} - \Delta_{2}} \right)^{2}}.} \\
\end{matrix}$$

The above formula is for the equal sample size. If the sample size for larger group is *c* times of smaller group, a factor (*f*) is applied to the smaller group which is given by *f* = (*c* + 1)/2*c*, in this case, the sample size of the smaller group is *n*~1~ = *f*^∗^*n* and that of the larger group is *n*~2~ = *c*^∗^*n*~1~, where *Z~α~* is the value of the standard normal variate corresponding to *α* level of significance, *Z~β~* is the standard normal deviate for desired power, Δ is the mean change in the parameter, and *σ* is the standard deviation of the change in the parameter.

The analysis included profiling of subjects by different sociodemographic parameters. For the intervention as well as the control group, the average values with SD have been computed for baseline as well as endline. Importantly, the improvements in parameters \[endline (postintervention) versus baseline\] have been estimated along with standard errors to test for their significance using the paired *t*-test. For comparing the significance of change in parameters in the intervention group over and above the control group, two sample *t*-tests have been used. *p* value \< 0.05 is considered statistically significant. SPSS software (IBM SPSS Statistics 24.0) has been used for statistical analysis.

2.2. Site and Subject Recruitment {#sec2.2}
---------------------------------

Worksites were eligible if they had not hosted a weight loss or any other wellness programme during the past 6 months, were easily accessible by public transportation, and had the basic infrastructure to hold on-site programmes and physical activity training sessions. We projected two sites as active intervention sites and other two as delayed intervention sites, labelled as control worksites. We then selected 4 worksites (both the public and private), from the different sites across Delhi and National Capital Region. The trial was initiated in 2014 after obtaining certification from Institutional Review Board. Initially, we contacted the human resource department of the worksites to explain the project and also whether their site would be intervention or control.

Inclusion criteria were willingness to participate, age group of 25--55 yrs., and having BMI ≥ 23 kg/m^2^, that is, overweight subjects \[[@B8]\]. Exclusion criteria included previously diagnosed patients with diabetes, coronary artery disease, receiving medication(s) within the last one month which could potentially influence insulin secretion, insulin sensitivity, or weight, having severe end-organ damage or chronic diseases, and pregnant and lactating women, etc. After rapport building and sensitization, we screened 598 participants in both the groups then randomly selected 180 subjects in the intervention site and 130 in the control site by random-generated numbers ([Figure 1](#fig1){ref-type="fig"}). All subjects were fully informed about the purpose of the study, and a written informed consent (approved by Institutional Review Board) was obtained from each of them.

2.3. Interventions {#sec2.3}
------------------

A multicomponent intervention was implemented for 6 months for active intervention sites. The variables recorded at baseline and after intervention were demographic information, behavioural risk factors (tobacco and alcohol consumption), dietary intake, physical activity pattern, anthropometric measurements, blood pressure examination, and biochemical investigations. Tobacco consumption included data on self-reported duration, frequency, and quantity. Self-reported alcohol intake data were collected, and subjects were classified as present consumer, past consumer, and nonconsumer.

The sessions and trainings were led by an expert team of physicians, nutritionist, and physical trainer. The interventions were designed for participants only but the sessions were open to the whole worksite employees. Over a period of 6 months, different intervention strategies were followed to increase the employee awareness and improvement in knowledge, attitude, and practices to get the expected results. Participants in the intervention group received detailed sessions on the different topics related to healthy living, diet, and physical activity. Two sessions on each topic were conducted in the intervention sites every 15 days for the duration of 45--60 minutes. Subsequently, in these sessions, reinforcement and need-based advice were provided. The nutrition topics included healthy eating pattern and food articles, eating outside home, portion control, choice of oils, correct cooking methods, how to read the food labels, and eating during traditional Indian festive seasons based on dietary guidelines for Indians \[[@B9]\]. Two physical activity training sessions were given to explain the best practices in physical activity as per guidelines for Asian Indians \[[@B10]\] and to encourage them to continue physical activity supported by use of pedometers. Stress management sessions were also provided to the employees to cope up with the workplace and other kinds of stress. We tracked the compliance of lifestyle changes with the text messages from a smartphone, digital health platform, e-mails, and repeated phone calls. The participants in the control sites (delayed intervention) did not receive any kind of intervention but were given general health talk twice in six months.

2.4. Measurements {#sec2.4}
-----------------

Blood pressure was recorded in a sitting position after 5 min rest with a mercury sphygmomanometer according to the standard guidelines. If one abnormal reading was observed, a second reading was recorded after 10 min of rest. For anthropometric measurements, weight was recorded to the nearest 0.1 kg and height to the nearest 0.1 cm. The BMI was calculated as weight (kg)/height (m)^2^. All the circumferences were measured by using flexible, nonstretchable tape. Waist circumference was measured midway between iliac crest and costal margin, and the hip circumference was measured at the maximum circumference of buttocks with the subject wearing minimum clothes. The mean of three readings of each was taken for the calculation of waist-hip ratio (W-HR). Biceps, triceps, subscapular, and suprailiac skinfolds were measured using Lange skinfold caliper (Beta Technology Inc., Santa Cruz, CA, USA). For biceps skinfold, with the right arm pendant, the fat pad was measured at the level of the nipple line, and triceps fat pad was measured midway between acromion process of scapula and olecranon process. Fat pads at the inferior angle of scapula, and superiorly on iliac crest directly in the midaxillary line, were measured for subscapular and suprailiac skinfolds. All skinfolds were measured to the nearest mm. A mean of three readings was recorded at each site.

Detailed dietary records were obtained from a subsample of subjects from the intervention group (*n*, 38) and the control group (*n*, 25). The food frequency questionnaire tool was used to measure habitual dietary intake \[[@B11]\]. The energy expenditure was assessed by using global physical activity questionnaire (GPAQ) \[[@B12]\] in a subsample of the intervention group (*n*, 85) and the control group (*n*, 80), and metabolic equivalent of task (MET) values were calculated.

2.5. Biochemical Investigations {#sec2.5}
-------------------------------

Biochemical investigations included fasting blood glucose (FBG) and serum lipids \[total cholesterol (TC), serum triglyceride (TG), and high-density lipoprotein cholesterol (HDL-c)\] taken after 10--12 hours of overnight fasting and as previously analysed \[[@B13]\]. The value of low-density lipoprotein cholesterol (LDL-c) was calculated according to Friedewald\'s equation \[[@B14]\].

2.6. Definitions {#sec2.6}
----------------

Overweight and obesity were defined as BMI ≥ 23--24.9 kg/m^2^ and BMI ≥ 25 kg/m^2^, respectively \[[@B8]\]. Waist circumference cutoffs of ≥90 cm for males and ≥80 cm for females were considered an indicator of abdominal obesity \[[@B8]\]. High W-HR was defined as ≥0.90 in males and ≥0.80 in females \[[@B8]\]. Central (sum of subscapular and suprailiac) and peripheral (sum of biceps and triceps) skinfold thicknesses were calculated. The sum of all skinfolds (∑4SF) was also calculated, and a value of ≥53.8 mm was taken as excess skinfold since it indicates the presence of insulin resistance \[[@B15]\]. Impaired fasting glucose and T2DM were diagnosed according to the diagnostic criteria of the American Diabetic Association \[[@B16]\]. Metabolic syndrome was defined as the presence of three or more of the following abnormalities: abdominal obesity (defined as waist circumference ≥ 90 cm for men and ≥80 cm for women), raised systolic blood pressure (SBP) ≥ 130 mmHg or diastolic blood pressure (DBP) ≥ 85 mmHg, treatment of previously diagnosed hypertension, FBG ≥ 100 mg/dl treatment of, previously diagnosed T2DM, TG level ≥ 150 mg/dl or specific treatment for this lipid abnormality, HDL-c ≤ 40 mg/dl in males and ≤50 mg/dl in females, or specific treatment for this lipid abnormality \[[@B17]\].

3. Results {#sec3}
==========

The baseline demographic characteristics of the participants in the intervention and the control group have been provided in [Table 1](#tab1){ref-type="table"}. High prevalence of obesity, abdominal obesity, and high subcutaneous adiposity was seen in the control and intervention groups ([Table 2](#tab2){ref-type="table"}). At the baseline, 95% individuals had at least one cardiovascular risk factor. There was no significant difference observed at the baseline in anthropometric, biochemical, and clinical parameters in both the groups ([Table 3](#tab3){ref-type="table"}).

Intervention resulted with significant decrease in the mean values of weight, BMI, waist circumference, hip circumference, W-HR, all the four skinfolds (biceps, triceps, subscapular, and suprailiac), FBG, TG, and increase in HDL-c in the intervention group. There was no significant difference observed in the mean values of all these parameters except FBG and three skinfolds (biceps, triceps, and subscapular) in the control group after 6 months ([Table 4](#tab4){ref-type="table"}). More than 5% weight loss was observed in 12% of the individuals in the intervention group as compared to only 4% of the individuals in the control group. Further, significant decrease in the skinfold measurements (mm) was seen in the intervention versus control group; biceps (1.8 ± 2.3 versus 0.95 ± 1.57), triceps (3.54 ± 3.67 versus 0.90 ± 2.70), subscapular (3.38 ± 4.21 versus 1.01 ± 3.35), and suprailiac (3.76 ± 3.79 versus 0.64 ± 3.53), respectively. Similarly, central and peripheral skinfolds (mm) in the intervention group decreased significantly as compared to the control group (7.14 ± 8.0 versus 1.65 ± 6.87 and 5.42 ± 5.92 versus 1.84 ± 5.92, resp.) ([Table 4](#tab4){ref-type="table"}). As a result, the sum of all the skinfold measurements in the intervention group decreased significantly more than the control group (12.51 ± 10.38 versus 3.50 ± 8.18, resp.) ([Figure 2](#fig2){ref-type="fig"}). Further subscapular/triceps (SS/T) ratio increased from 1.37 to 1.48 in the intervention group, as opposed to the decrease in the control group (1.48 to 1.42). [Table 5](#tab5){ref-type="table"} describes changes in the strata, from abnormal to normal, of obesity, abdominal obesity, excess skinfold thickness, lipids, and glucose values after intervention. Specifically, individuals with excess sum of all the skinfolds were reduced significantly in the intervention group as compared to the control group after intervention.

Changes in the clustering of risk factors of metabolic syndrome have been shown in [Figure 3](#fig3){ref-type="fig"}. It is interesting to note that individuals with the reduction in the number of five, four, and three risk factors are more in the intervention group after intervention; status of many of those changed to two factors or one. It is of note that very few have reverted to nil or no risk factor profile in both the groups. Specifically, individuals with 3 risk factors decreased from 27% to 19% in the intervention group as compared to the increase from 21% to 22% in the control group. Individuals with four factors decreased more in the intervention as compared to the control groups (14% to 8% versus 18% to 15%, resp.). Similarly, in the intervention group, 5 risk factors decreased from 7% to 3% individuals but remained the same (from 4% to 5%) in the control group.

The subsample assessment showed a significant reduction in the sedentary lifestyle. More individuals converted from sedentary to more active lifestyle (67% to 55%) in the intervention group ([Figure 4(b)](#fig4){ref-type="fig"}) as compared to the control group (69% to 65%) ([Figure 4(d)](#fig4){ref-type="fig"}). Dietary behaviour also improved in terms of decrease in total calorie intake and fat consumption ([Figure 5(b)](#fig5){ref-type="fig"}).

4. Discussion {#sec4}
=============

In this randomized control trial, high prevalence of obesity, abdominal obesity, hypertension, dyslipidemia, and metabolic syndrome was observed in relatively young and overweight individuals working in corporate setups in North India. Further, multicomponent interventions based on face-to-face interactions as well as with the use of digital platform showed significant decrease in weight, BMI, waist circumference, hip circumference, W-HR, both peripheral and central skinfolds, and triglycerides and increase in HDL-c. It is important to note change in clustering of risk profile status from multiple clustering (3--5 per individual) to lesser clustering.

Worksite intervention programs have been rarely done in India. In particular, a closely related intervention, tobacco control at worksites, has been eminently successful, backed by tight legal regulations in India. A recent study on 20 worksites in manufacturing sector successfully demonstrated doubling of the 6-month smoking cessation rates among workers in the intervention worksites compared to those in the control sites \[[@B18]\].

In a study carried out in 10 different industrial sites representing multiple regions of India, the lifestyle-based intervention surveys and cohort analysis showed a significant relative reduction in the cardiovascular risk factors except in serum triglycerides in the intervention group versus the control group \[[@B19]\]. Further, in South India, a healthy workplace model was evaluated in workers of a software industry. In this study, high levels of risk factors, obesity (55%), and hypertension (15%) were recorded. Based on these data, modifications in the workplace targeting physical and psychosocial work environment were suggested by the authors \[[@B20]\]. In the current study, we show that clustering of multiple risk factors was reduced, along with weight, abdominal, and generalized adiposity, which may contribute to prevention of diabetes and cardiovascular disease. Most importantly, behaviour changes were seen in our study after intervention, with significant improvements in physical activity and change in diet towards healthier options.

We assessed skinfold thicknesses at different sites, which has not been previously done in any such study. These skinfold measurements show magnitude and distribution of subcutaneous adiposity in an individual. It is important to note that subcutaneous adipose tissue is high in Asian Indians \[[@B1]\]. The importance of skinfold measurements, specifically subscapular/triceps ratio (central obesity), was initially shown by Haffner et al. \[[@B21]\] in Mexican Americans. In this study, using multiple logistic regressions with age, ethnicity, BMI, and central obesity as covariates, the overall obesity was positively associated with T2DM prevalence in both sexes but central obesity was related to prevalence of T2DM only in women. In another analysis on Mexican Americans by the same group, subscapular/triceps ratio and W-HR both were associated with high rates of diabetes, low HDL-c levels, and high triglyceride level \[[@B22]\]. It is important to note that in the current trial, the most impressive changes after the intervention were observed in skinfold thicknesses. Specifically, the sum of subscapular and suprailiac skinfold (indicative of truncal subcutaneous adiposity) was significantly reduced in intervention group (7.14 mm) as compared to the control group (1.65 mm). Further, we also show that 28% participants in the intervention group had decreased sum of skinfolds below the threshold that signifies insulin resistance versus 9% in the control group. Importance of excess truncal subcutaneous tissue in the context of dysmetabolic state in Asian Indians has been emphasized previously. Specifically, excess truncal subcutaneous adipose tissue (as shown by central skinfolds) showed close correlation with insulin resistance and metabolic syndrome in Asian Indians \[[@B23]\]. In a previous study on Asian Indian adolescents, using binary recursive analysis, we showed that excess sums of the four skinfolds (central and peripheral) are important determinants of insulin resistance \[[@B24]\]. In a recent comparative study between nondiabetic Asian Indians with nonalcoholic fatty liver disease (NAFLD) versus nondiabetic individuals without NAFLD, subscapular, suprailiac, and central skinfolds were significantly higher in the former \[[@B25]\], signifying relationship of truncal subcutaneous adiposity to NAFLD, a central facet of metabolic syndrome. Interestingly, as compared to White Caucasians, South Asians have larger adipocytes from subcutaneous adipose tissue, associated with significant insulin resistance. Further, subcutaneous adipocyte area was higher in Asian Indians with increased body fat percentage and hepatic fat as compared to White Caucasians with similar BMI \[[@B26]\]. Finally, subcutaneous abdominal adipose tissue mRNA expression was significantly higher for genes associated with inflammation and CD68, MAC1, and MCP1 in Asian Indians compared with whites, meaning increased inflammation generated from subcutaneous adipocytes in the former \[[@B27]\].

It is encouraging to report significant decrease in triglycerides after the intervention (11.0 mg/dl in the intervention group versus 0.12 mg/dl in the control group) which is different to previous worksite intervention study in India \[[@B19]\]. Atherogenic dyslipidemia is particularly common in South Asians and has been shown to have a strong association with T2DM, metabolic syndrome, and coronary heart disease (CHD). Interestingly, triglyceride levels have been shown to rise steeply before 20 years age to maximally in 30--39 years age in Asian Indians \[[@B3]\]. In particular, low HDL levels are common in Asian Indians and are lower than that seen in Whites \[[@B1]\]. Further, HDL particles also appear to be smaller, dysfunctional, and proatherogenic in South Asians \[[@B1]\]. Whether such betterment of serum triglycerides with increase in HDL-c levels leads to any cardiovascular benefit continues to be researched. In a recent study on 28,318 members (aged 30 to 90 years), the presence of atherogenic dyslipidemia was associated with the highest age-adjusted CHD events/1000 patient years after multiple adjustments and even in those with LDL-c \< 100 mg/dl \[[@B28]\]. Hence, any such decrease in triglycerides and increase in HDL-c levels after intervention, as has been shown in our study, are likely to decrease cardiovascular risk. Interestingly, increased thickness of truncal adipose tissue, as seen in our study, is typical of Asian Indians and could be strongly related to high triglycerides and low HDL-c levels from early age \[[@B29]\].

Finally, there are a few limitations of our study; the study was of a short-term duration. The future trials should include more number of participants with lesser number of subjects who are lost to follow-ups and should be conducted over a longer period of time.

Furthermore, physical activity and dietary habit data could be collected in larger number of individuals. Also, more measures of glycaemia (glycosylated hemoglobin) and inflammatory markers (high sensitivity C-reactive protein) could be included. The strength of our study is the design (randomized trial) and clinical measurement of truncal subcutaneous adiposity, which is important adiposity measure in Asian Indians.

5. Conclusion {#sec5}
=============

In conclusion, this multicomponent lifestyle intervention study conducted in overweight worksite individuals with the cardiometabolic risk factors was successful in achieving of reduction in weight, excess subcutaneous fat, and cardiometabolic risk factors after 6 months of active intervention. Results of this study are reasonably convincing to encourage other worksites in India to implement similar kind of multicomponent interventions.
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![Screening and recruitment. ^∗^See text for assessment details. ^∗∗^See text for methodology of interventions.](JDR2017-7254174.001){#fig1}

![Changes in absolute values of skinfold thickness and sum of skinfolds after intervention. All the values are significant \<0.05. Values placed above bars are absolute values of respective skinfolds in mm. See [Table 5](#tab5){ref-type="table"} for SD of skinfold measurements. ^∗^Central skinfold is the sum of subscapular and suprailiac skinfolds, peripheral skinfold is the sum of biceps and triceps skinfolds, and the sum of skinfolds is the sum of all the 4 skinfolds (∑4SF, biceps, triceps, subscapular, and suprailiac).](JDR2017-7254174.002){#fig2}

![Changes in clustering of risk factors comprising metabolic syndrome before and after intervention. All the values are in the percentage. Please see text for definitions of risk factors.](JDR2017-7254174.003){#fig3}

![Change in physical activity profile after intervention. Showing physical activity profile. (a) Preintervention in intervention group (*n*, 85). (b) Postintervention in the intervention group (*n*, 80) (c) Preintervention in the control group (*n*, 85). (d) Postintervention in the control group (*n*, 80).](JDR2017-7254174.004){#fig4}

![Changes in dietary profile after intervention. Showing dietary profile. (a) Preintervention in the intervention group (*n*, 38). (b) Postintervention in the intervention group (*n*, 25). (c) Preintervention in the control group (*n*, 38). (d) Postintervention in the control group (*n*, 25).](JDR2017-7254174.005){#fig5}

###### 

Baseline characteristics.

  ---------------------------------------------------------------------------------------------------------------
  Variable                    Intervention\                             Control\
                              Frequency in % or mean ± SD (*n* = 156)   Frequency in % or mean ± SD (*n* = 111)
  --------------------------- ----------------------------------------- -----------------------------------------
  Mean age in years ± SD      35.8 ± 7.6                                39.0 ± 8.7

  Males                       87.9                                      82.5

  Females                     12.1                                      17.5

  Marital status                                                        

   Married                    85.7                                      89.3

   Single education           14.3                                      10.7

   Senior secondary           4.4                                       2.3

  Graduate                    47.8                                      45.2

   Postgraduate               46.7                                      52.0

   Doctorate                  1.1                                       0.6

  Household income                                                      

   More than 75(000) INR^∗^   73.6                                      65.5

   65--75 (000) INR           9.9                                       6.8

   55--65 (000) INR           4.9                                       7.9

   45--55 (000) INR           6.0                                       9.6

   Less than 45 (000) INR     5.4                                       10.2

  Tobacco user                                                          

   Never                      79.1                                      76.8

   Current                    15.4                                      15.8

   Past                       5.5                                       7.3

  Alcohol user                                                          

   Never                      45.1                                      42.9

   Current                    47.3                                      46.3

   Past                       7.7                                       10.7
  ---------------------------------------------------------------------------------------------------------------

^∗^INR: Indian national rupee.

###### 

Prevalence (%) of high/abnormal values of risk factors^∗^ at baseline.

  Variable                                       Intervention       Control
  ---------------------------------------------- ------------------ -------------------
  Obesity                                        90.9               80.2
                                                 M: 91.9; F: 84.2   M:77.9; F:93.8
  Sum of skinfolds (mm)                          70.3               75.9
                                                 M: 67.6; F: 89.5   M: 71.7; F: 100.0
  Waist circumference (cm)                       93.5               84.3
                                                 M: 94.9; F: 84.2   M:82.6; F:93.8
  Waist-hip ratio                                91.1               90.7
                                                 M: 92.6; F:78.9    M:91.3; F:87.5
  Systolic blood pressure (mmHg)                 31.2               31.0
                                                 M:34.8; F:5.3      M:31.8; F: 26.7
  Diastolic blood pressure (mmHg)                40.3               44.0
                                                 M: 43.7; F: 15.8   M: 48.2; F: 20
  Fasting blood glucose (mg/dl)                  25.7               30.6
                                                 M: 29.2; F: 0.0    M: 30.6; F:30.8
  Total cholesterol (mg/dl)                      33.1               29.4
                                                 M:32.3; F: 38.9    M: 32.2; F:13.3
  High-density lipoprotein cholesterol (mg/dl)   56.8               63.7
                                                 M: 55.4; F: 66.7   M: 62.1; F:73.3
  Low-density lipoprotein cholesterol (mg/dl)    72.3               74.5
                                                 M: 73.8; F: 61.1   M: 73.6; F:80.0
  Serum triglycerides (mg/dl)                    37.2               33.3
                                                 M:40.0; F:16.7     M: 35.6; F:20.0

All values in percentages. ^∗^See text for definitions of abnormal values.

###### 

Mean values of anthropometric, clinical, and biochemical profiles at baseline.

  Parameter                                      Intervention   Control          Intervention-control (Δ)   Statistical significance of intervention versus control at baseline                    
  ---------------------------------------------- -------------- ---------------- -------------------------- --------------------------------------------------------------------- ------- -------- -------
  Weight (kg)                                    156            81.67 ± 10.72    111                        80.89 ± 12.24                                                         0.77    0.536    0.592
  BMI (kg/m^2^)                                  156            28.21 ± 2.89     111                        28.20 ± 3.59                                                          0.02    0.039    0.969
  Waist circumference (cm)                       155            98.90 ± 8.58     111                        98.89 ± 9.81                                                          0.25    0.218    0.827
  Hip circumference(cm)                          155            103.70 ± 5.72    111                        103.84 ± 7.83                                                         −0.14   0.161    0.872
  Waist-hip ratio                                155            0.95 ± 0.06      111                        0.96 ± 0.06                                                           −0.01   0.798    0.425
  Skinfolds (mm)                                                                                                                                                                                   
   Biceps                                        155            8.69 ± 4.02      108                        9.26 ± 3.86                                                           −0.56   1.148    0.251
   Triceps                                       155            16.64 ± 5.69     108                        16.33 ± 5.66                                                          0.32    0.443    0.658
   Subscapular                                   155            22.83 ± 6.15     108                        22.88 ± 6.08                                                          −0.05   0.067    0.947
   Suprailiac                                    155            18.11 ± 6.34     108                        18.80 ± 6.76                                                          −0.69   0.831    0.406
   Sum of peripheral skinfolds                   155            25.3 ± 10.13     108                        25.6 ± 9.72                                                           −0.25   0.201    0.841
   Sum of central skinfolds                      155            40.9 ± 12.27     108                        41.7 ± 12.93                                                          −0.80   0.504    0.614
   Sum of 4 skinfolds (∑4SF)                     155            66.28 ± 18.74    108                        67.27 ± 18.84                                                         −0.99   0.419    0.675
  Systolic blood pressure (mmHg)                 154            122.04 ± 13.04   100                        124.67 ± 13.40                                                        −2.63   1.547    0.122
  Diastolic blood pressure (mmHg)                154            82.61 ± 8.95     100                        83.87 ± 9.86                                                          −1.25   1.025    0.305
  Fasting blood glucose (mg/dl)                  148            96.52 ± 12.29    102                        98.03 ± 10.41                                                         −1.51   −0.998   0.318
  Total cholesterol (mg/dl)                      148            187.74 ± 36.00   102                        181.63 ± 36.72                                                        6.10    1.302    0.193
  High-density lipoprotein cholesterol (mg/dl)   148            40.90 ± 9.51     102                        40.10 ± 8.32                                                          0.80    0.700    0.484
  Low-density lipoprotein cholesterol (mg/dl)    148            118.00 ± 26.98   102                        117.57 ± 32.38                                                        0.43    0.111    0.912
  Serum triglycerides (mg/dl)                    148            145.74 ± 80.4    102                        137.31 ± 62.48                                                        8.43    0.931    0.352

###### 

Changes in values of body composition, blood pressure, and metabolic factors after intervention.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Variable                                    *N*             Intervention mean ± SD   *p* value       *N*             Control mean ± SD   *p* value       Change in intervention versus control Δ1-Δ2   *p* value
  ------------------------------- ----------- --------------- ------------------------ --------------- --------------- ------------------- --------------- --------------------------------------------- --------------
  Weight (kg)                     Baseline\   156\            81.67 ± 10.72\           *p* \< 0.001    111             80.89 ± 12.24\      *p* = 0.0455    1.22                                          *p* \< 0.001
                                  Follow-up   156             80.07 ± 10.50                                            80.51 ± 12.31                                                                     

  Difference                                  1.60 ± 2.76                                              0.38 ± 2.03                                                                                       

  BMI (kg/m^2^)                   Baseline\   156\            28.21 ± 2.89\            *p* \< 0.001    112             28.20 ± 3.59\       *p* = 0.0278    0.39                                          *p* \< 0.001
                                  Follow-up   156             27.6 ± 2.8                                               28.04 ± 3.62                                                                      

  Difference                                  0.55 ± 0.96                              112             0.16 ± 0.75                                                                                       

  Waist circumference (cm)        Baseline\   155\            98.90 ± 8.58\            *p* \< 0.001    111             98.89 ± 9.81\       *p* = 0.1902    2.11                                          *p* \< 0.001
                                  Follow-up   155             97.04 ± 8.18                                             99.20 ± 9.81                                                                      

  Difference                                  1.87 ± 3.49                              111             −0.31 ± 9.81                                                                                      

  Hip circumference (cm)          Baseline\   155\            103.70 ± 5.72\           *p* \< 0.001    111             103.84 ± 7.83\      *p* = 0.3222    1.00                                          *p* \< 0.001
                                  Follow-up   155             102.46 ± 5.69                                            103.60 ± 8.08                                                                     

  Difference                                  1.23 ± 2.94                              111             0.23 ± 2.49                                                                                       

  Waist-hip ratio                 Baseline\   155\            0.954 ± 0.062\           *p* = 0.0239    111             0.950 ± 0.064\      *p* = 0.064     0.01                                          *p* \< 0.001
                                  Follow-up   155             0.947 ± 0.061                                            0.955 ± 0.062                                                                     

  Difference                                  0.007 ± 0.029                            111             0.005 ± 0.028                                                                                     

  Skinfold biceps (mm)            Baseline\   155\            8.69 ± 4.02\             *p* \< 0.001    108             9.26 ± 3.86\        *p* \< 0.001    0.89                                          *p* \< 0.001
                                  Follow-up   155             6.85 ± 2.95                                              8.31 ± 3.68                                                                       

  Difference                                  1.84 ± 2.26                              108             0.95 ± 1.57                                                                                       

  Triceps (mm)                    Baseline\   155\            16.64 ± 5.69\            *p* \< 0.001    108             16.33 ± 5.66\       *p* \< 0.001    2.64                                          *p* \< 0.001
                                  Follow-up   155             13.11 ± 5.19                                             15.43 ± 5.41                                                                      

  Difference                                  3.54 ± 3.67                              108             0.90 ± 2.70                                                                                       

  Subscapular (mm)                Baseline\   155\            22.83 ± 6.15\            *p* \< 0.0001   108             22.88 ± 6.08\       *p* \< 0.001    2.36                                          *p* \< 0.001
                                  Follow-up   155             19.45 ± 4.91                                             21.87 ± 5.22                                                                      

  Difference                                  3.38 ± 4.21                              108             1.01 ± 3.35                                                                                       

  Suprailiac (mm)                 Baseline\   155\            18.11 ± 6.34\            *p* \< 0.001    108             18.80 ± 6.76\       *p* = 0.0601    3.12                                          *p* \< 0.001
                                  Follow-up   155             14.35 ± 5.18                                             18.16 ± 6.31                                                                      

  Difference                                  3.76 ± 3.79                              108             0.64 ± 3.53                                                                                       

  Central skinfolds (mm)^∗^       Baseline\   155\            40.94 ± 12.27\           *p* \< 0.001    108             41.68 ± 12.93\      *p* = 0.0102    5.40                                          *p* \< 0.001
                                  Follow-up   155             33.8 ± 10.14                                             40.03 ± 11.60                                                                     

  Difference                                  7.14 ± 8.00                              108             1.65 ± 6.87                                                                                       

  Peripheral skinfolds (mm)^∗∗^   Baseline\   155\            25.29 ± 10.13\           *p* \< 0.001    108             25.59 ± 9.52\       *p* \< 0.001    3.53                                          *p* \< 0.001
                                  Follow-up   155             19.87 ± 8.19                                             23.74 ± 9.10                                                                      

  Difference                                  5.42 ± 5.92                              108             1.84 ± 5.92                                                                                       

  ∑4SF skinfolds (mm)^∗∗∗^        Baseline\   155\            66.28 ± 18.74\           *p* \< 0.001    108             67.27 ± 18.84\      *p* \< 0.001    9.02                                          *p* \< 0.001
                                  Follow-up   155             53.77 ± 15.37                                            63.77 ± 17.39                                                                     

  Difference                                  12.51 ± 10.38                            108             3.50 ± 8.18                                                                                       

  SBP (mmHg)                      Baseline\   154\            122.04 ± 13.04\          *p* = 0.4413    100             124.67 ± 13.40\     *p* = 0.8572    0.86                                          *p* = 0.5505
                                  Follow-up   154             121.39 ± 12.64                                           124.89 ± 12.87                                                                    

  Difference                                  0.65 ± 10.44                             100             −0.22 ± 11.77                                                                                     

  DBP (mmHg)                      Baseline\   154\            82.61 ± 8.95\            *p* \< 0.001    100             83.87 ± 9.86\       *p* = \<0.001   −0.65                                         *p* = 0.5734
                                  Follow-up   154             80.29 ± 9.92                                             80.89 ± 7.83                                                                      

  Difference                                  2.32 ± 7.57                              100             2.98 ± 9.88                                                                                       

  FBG (mg/dl)                     Baseline\   148\            96.52 ± 12.29\           *p* \< 0.001    102             98.03 ± 10.41\      *p* \< 0.001    0.63                                          *p* = 0.4319
                                  Follow-up   148             93.63 ± 11.64                                            95.77 ± 9.49                                                                      

  Difference                                  2.89 ± 6.48                              102             2.26 ± 5.88                                                                                       

  TC (mg/dl)                      Baseline\   148\            187.74 ± 36.00\          *p* = 0.0164    102             181.63 ± 36.72\     *p* = 0.2301    7.55                                          *p* = 0.0134
                                  Follow-up   148             182.96 ± 36.35                                           184.40 ± 32.11                                                                    

  Difference                      148         4.78 ± 24.17                             102             −2.77 ± 23.37                                                                                     

  HDL-c (mg/dl)                   Baseline\   148\            40.90 ± 9.51\            *p* \< 0.001    102             40.10 ± 8.32\       *p* = 0.4179    −1.81                                         *p* = 0.0051
                                  Follow-up   148             43.10 ± 8.86                                             40.49 ± 8.10                                                                      

  Difference                                  −2.20 ± 5.37                             102             −0.39 ± 4.79                                                                                      

  LDL-c (mg/dl)                   Baseline\   148\            118.00 ± 26.98\          *p* = 0.4654    102             117.57 ± 32.38\     *p* = 0.5419    2.81                                          *p* = 0.3498
                                  Follow-up   148             116.60 ± 30.54                                           118.98 ± 29.95                                                                    

  Difference                                  1.40 ± 23.20                             102             −1.41 ± 23.42                                                                                     

  TG (mg/dl)                      Baseline\   148\            145.74 ± 80.41\          *p* = 0.0039    102             137.31 ± 62.48\     *p* = 0.9681    10.95                                         *p* = 0.0218
                                  Follow-up   148             134.67 ± 71.09                                           137.19 ± 64.46                                                                    

  Difference                                  11.07 ± 46.56                            102             0.12 ± 28.85                                                                                      
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^∗^Central skinfold is the sum of subscapular and suprailiac skinfolds. ^∗∗^Peripheral skinfold is the sum of biceps and triceps skinfolds. ^∗∗∗^∑4SF is the sum of all 4 skinfolds (biceps, triceps, subscapular, and suprailiac); SBP: systolic blood pressure; DBP: diastolic blood pressure; FBG: fasting blood glucose; TC: total cholesterol; HDL-c: high-density lipoprotein cholesterol; LDL-c: low-density lipoprotein cholesterol; TG: serum triglycerides.

###### 

Changes in abnormal profile of various factors to normal after intervention.

  Parameters                                      Intervention   Control   Statistical significance of change in intervention versus change in control                  
  ----------------------------------------------- -------------- --------- ----------------------------------------------------------------------------- ------ ------- --------
  Obesity (BMI ≥ 25 kg/m^2^)                      90.9           85.6      80.2                                                                          86.5   1.830   0.0673
  Sum of four skinfolds (∑4SF ≥ 53.8 mm)          70.3           42.6      75.9                                                                          66.7   2.263   0.0237
  Waist circumference (WC ≥ 90 cm M, ≥ 80 cm F)   93.5           92.3      84.3                                                                          85.2   0.089   0.0896
  Waist-hip ratio (≥0.9 M, ≥ 0.8 F)               91.0           91.0      90.7                                                                          90.7   0.175   0.8611
  SBP ≥ 130 mmHg                                  31.2           24.7      31                                                                            32     0.901   0.3675
  DBP ≥ 85 mmHg                                   40.3           30.5      44.0                                                                          30.0   0.492   0.6229
  FBG ≥ 100 mg/dl                                 25.7           18.9      30.6                                                                          22.8   0.005   0.9957
  Total cholesterol ≥ 200 mg/dl                   33.1           27.7      29.4                                                                          32.4   0.995   0.3195
  HDL (≤40 mg/dl in M and ≤50 mg/dl in F)         56.8           40.5      63.7                                                                          59.8   1.382   0.1669
  LDL (≥100 mg/dl)                                72.3           69.6      74.5                                                                          74.5   0.335   0.7376
  TG (≥150 mg/dl)                                 37.2           27.0      33.3                                                                          38.2   1.748   0.0805

All values are in percentages; SBP: systolic blood pressure; DBP: diastolic blood pressure; FBG: fasting blood glucose; HDL-c: high-density lipoprotein cholesterol; LDL-c: low-density lipoprotein cholesterol; TG: serum triglycerides; M: males; F: females.

[^1]: Academic Editor: Marco Songini
